Skip to content

Treatment Reality with Patients' Treatment Response in RE patients treated with low dose of PPIs via Web-based survey

Treatment Reality with Patients' Treatment Response in RE patients treated with low dose of PPIs via Web-based survey - The LILAC study (Treatment reality of Low dose PPIs for refLux and ACid regurgitation)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000017268
Enrollment
1200
Registered
2015-04-24
Start date
2015-04-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

None listed

Sponsors

AstraZeneca K.K. Medical
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Subjects aged 20 years or older at the time of providing informed consent. 2.Subjects with a diagnosis of reflux esophagitis by physician 3.Subjects who have been treated with low dose or PPI for at least 4 weeks to relief or maintain remission of heartburn and/or acid regurgitation

Exclusion criteria

Exclusion criteria: 1.Subjects suspected of poor capability follow instructions of the survey.

Design outcomes

Primary

MeasureTime frame
The proportion of patient which all the item are selected to "1 day" or "nothing " of question 1,2,5,6 in GerdQ

Secondary

MeasureTime frame
The item raised below is estimated. 1. The GerdQ score Mean of the whole questions of GerdQ 2. Healthy related QOL evaluation Mean of the SF-8TM J core 3. Patient's sentiment to a disease and treatment original questionnaire are which consiets of seven scale and enable to select more than two items at the same time. 4. The degree of the subjective symptom Sevenity of the subjective symptom (heartburn, acid reflux, epigastralgia, belch, nausea, vomit, dysphagia, epigastric distress (stomach leaning) and inappetence)

Countries

Japan

Contacts

Public ContactHitoshi Osawa

Mebix, Inc. Research Promotion

re-research@mebix.co.jp03-6229-8936

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026